TL;DR
For decades, an experimental anti-aging treatment meant joining a trial or leaving the country. Now there is a third door. Montana has seated the first state board that can clear unapproved therapies for clinics to sell, as long as the treatment has passed its first round of human safety testing. At the same time, a research paper confirms that gene therapies aimed at aging are already being injected into paying clients abroad, with almost no published results. The result is a new kind of market: legal in one American state, unregulated overseas, and running ahead of the evidence. For people willing to pay and take the risk, the future is arriving early. For everyone else, it will show whether a state-run shortcut can produce real data or only real bills.
Below the line, for paid subscribers: The full story: where it stands, how we got here and what's dated next; our Odds board on 4 milestones, starting with "Montana's review board clears its first experimental therapy by 2027"; and every source.